#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

New Methods of the Treatment of Retinal Dystrophies


Authors: H. Langrová;  V. Kratochvílová
Authors place of work: Lékařská fakulta v Hradci Králové přednosta prof. MUDr. Pavel Rozsíval, CSc., FEBO ;  Oční klinika, Univerzita Karlova v Praze
Published in the journal: Čes. a slov. Oftal., 69, 2013, No. 3, p. 106-109
Category: Original Article

Summary

There is a brief review of actual treatment possibilities of retinal dystrophies in this article. Vitaminotherapy, electrostimulation and gene therapy are used in beginning stages of disorders. The efficiency of neuroprotective substances that are applied intravitreally using encapsulated cell technology is examined, as well as influence of systemic immunotherapy. In advanced stages of retinal diseases that are connected with loss of photoreceptors are used electronic retinal prostheses. Effectivity of treatment with stem cells, transplantation of cells and tissues and optogenetic therapy are evaluated.

Key words:
new therapeutic methods, retinal dystrophy


Zdroje

1. Adamus, G, Wang, S, Kyger, M et. al.: Systemic immunotherapy delays photoreceptor cell loss and prevents vascular pathology in Royal College of Surgeons rats. Mol Vi., 18; 2012: 2323–2237.

2. Berson, EL, Rosner, B, Sandberg, MA et al.: A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol, 111; 1993, 6: 761–772.

3. Berson, EL, Rosner, B, Sandberg, MA et al.: Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol, 128; 2010, 4: 403–411.

4. Berson, EL, Rosner, B, Sandberg, MA et al.: Ω-3 intake and visual acuity in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol, 130; 2012, 6: 707–711.

5. Gekeler, F. und Arbeitsgruppe Elektrostimulation des Department für Augenheilkunde am Universitäts-Klinikum Tübingen. [Transcorneal electrostimulation]. Ophthalmologe, 109; 2012, 2: 129–135.

6. Humayun, MS, Dorn, JD, da Cruz, L et al.: Argus II Study Group. Interim results from the international trial of Second Sight‘s visual prosthesis. Ophthalmology, 119; 2012, 4: 779–788.

7. Chow, AY, Chow, VY, Packo, KH et al.: The artificial silicon retina microchip for the treatment of vision loss from retinitis pigmentosa. Arch Ophthalmol, 122; 2004, 4: 460–469.

8. Jacobson, SG, Cideciyan, AV, Ratnakaram, R et al.: Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol, 130; 2012, 1: 9–24.

9. Schatz A, Röck T, Naycheva L et al.: Transcorneal electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled exploratory study. Invest Ophthalmol Vis Sci, 52; 2011, 7: 4485–4496.

10. Schwartz, SD, Hubschman, JP, Heilwell, G et al.: Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet, 379; 2012, 9817: 713–720.

11. Šín M, Rehák M, Chrapek O et al.: Současné možnosti náhrady vidění nevidomých pacientů pomocí neuroprotéz. Čes Slov Oftalmol., 67, 2011, 1: 3–6.

12. Talcott KE, Ratnam K, Sundquist SM et al.: Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment. Invest Ophthalmol Vis Sci, 52; 2011, 5: 2219–2226.

13. Tibbetts, MD, Samuel, MA, Chang, TS et al.: Stem cell therapy for retinal disease. Curr Opin Ophthalmol, 23; 2012, 3: 226–234.

14. Zrenner, E, Bartz-Schmidt, KU, Benav, H et al.: Subretinal electronic chi ps allow blind patients to read letters and combine them to words. Proc Biol Sci, 278; 2011, 1711: 1489–1497.

Štítky
Ophthalmology
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#